Guard Therapeutics International (GUARD.ST) Stock Analysis & AI Equity Report
Guard Therapeutics International (GUARD.ST) overview
Guard Therapeutics International (GUARD.ST) stock analysis and AI equity research. For the latest completed financial year, 2025, Guard Therapeutics International reported revenue of SEK 0m and operating profit of SEK -108m; the year-end share price was 1.47 SEK and market capitalisation was SEK 26.5m. Guard Therapeutics International is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Guard Therapeutics International's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-07-27. Data will be refreshed during report generation.
About Guard Therapeutics International
Guard Therapeutics International AB is a Swedish clinical-stage biotechnology company focused on developing therapies for kidney disease. Its lead candidate, RMC-035, is being studied to protect the kidneys from injury in settings such as open-heart surgery, and the company also develops preclinical peptide-based programs derived from alpha-1-microglobulin. In June 2026, it announced a conditional reverse takeover with Disruptive Pharma.
Generate the Guard Therapeutics International report
Guard Therapeutics International is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Guard Therapeutics International and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Guard Therapeutics International
Each is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by what other analysts said the work added over the engine's report — a score out of five from people who had to read it to give it.